Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ShangPharma Announces Second Quarter 2011 Results


      News provided by

      ShangPharma Corporation

      Aug 22, 2011, 07:02 ET

      Share this article

      Share this article


      SHANGHAI, Aug. 22, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the quarter ended June 30, 2011.

      To help management and investors gain a better understanding of ShangPharma's operating performance, the Company presents certain non-GAAP measures, each of which excludes expenses relating to or the effect of share-based compensation. See "About Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Data" below for more information about the non-GAAP financial measures included in this press release.

      Second Quarter 2011 Highlights

      • Net revenues increased by 26.0% year-over-year to $27.5 million.
      • Net revenues from China-based customers increased 202.7% year-over-year to $2.7 million.  
      • GAAP gross profit increased by 23.6% year-over-year to $9.1 million. GAAP gross margin was 33.3%, compared with 33.9% in the second quarter of 2010.
      • Non-GAAP gross profit increased by 26.7% year-over-year to $9.5 million. Non-GAAP gross margin was 34.7% compared with 34.5% in the second quarter of 2010.
      • GAAP profit from operations decreased by 12.7% year-over-year to $2.8 million. GAAP operating margin was 10.3%, compared with 14.8% in the second quarter of 2010.
      • Non-GAAP profit from operations increased by 22.2% year-over-year to $4.2 million. Non-GAAP operating margin was 15.2% compared with 15.7% in the second quarter of 2010.
      • GAAP net income decreased by 19.0% year-over-year to $3.4 million. GAAP diluted earnings per ADS were $0.18, compared with $0.26 in the second quarter of 2010.
      • Non-GAAP net income increased by 9.0% year-over-year to $4.7 million.  Non-GAAP diluted earnings per ADS were $0.25, compared with $0.28 in the second quarter of 2010. The decrease is primarily due to the increase of weighted average outstanding ADSs as a result of our initial public offering in October 2010.
      • Total number of customers increased to 316 as of June 30, 2011 from 237 as of December 31, 2010 and 282 as of March 31, 2011.
      • The Company reaffirms its revenues, non-GAAP gross margin and capital expenditure guidance for the full year of 2011.

      Management Comment

      Michael Xin Hui, founder and Chief Executive Officer of ShangPharma, commented, "We are pleased to deliver another quarter of broad-based solid results. Our business lines grew as a result of our strategy to expand our technology platforms and customer base in different geographical areas to respond to the demands of our clients.

      "Our expanded integrated service offerings are allowing us to penetrate deeper into our existing customer base. We are successfully attracting new customers in the Chinese pharmaceutical industry, which is a nascent, but rapidly growing industry.  Revenues from our China-based customers rose by 202.7% year-over-year, and included a mix of both local pharmaceutical companies and smaller domestic laboratories, as well as major multi-national biotech and pharmaceutical companies' R&D centers in China, representing a great improvement on the diversification of our customer base.  Revenue from China-based customers increased to near 10% of total revenues due to strong demand from the local market. There is tremendous growth opportunity for our services in China, and we plan to further increase our China business while simultaneously increasing penetration to developed pharmaceutical markets.  We continue to do very well in terms of generating revenues from our top customers, which are largely major global pharmaceutical and biotechnology companies. We have continued to benefit from the trend that big major global pharmaceutical companies are increasing their outsourcing needs to China.

      "We are especially encouraged by the recent significant growth in our biologics services. We are expecting a strong performance for our biologics services in the coming third and fourth quarters.  These recent developments coupled with our growing reputation are helping to enhance our increasingly close partnerships with leading global and domestic companies, which will support our future growth."

      William Dai, Chief Financial Officer, added, "We achieved our second quarter objectives despite continued pressures from wage inflation, higher material costs and the appreciation of the Renminbi.  Despite these headwinds, we managed our expenses exceptionally well and continue to improve employee productivity. We generated sales growth of 26% year-over-year and 11% quarter-over-quarter while our headcount remained flat compared to the first quarter of 2011. We are also seeing benefits from investments we made into managerial and supporting infrastructure in 2010, while progress at our new facilities in Fengxian continues, and construction remains on schedule. We will focus on managing our costs in the second half of the year, and are confident that we will meet our financial guidance for 2011."

      Second Quarter 2011 Results

      Net revenues were $27.5 million, an increase of 26.0% from $21.8 million in the second quarter of 2010, primarily due to higher volumes from the Company's top customers, a larger customer base and expanded service offerings.  During the quarter, revenues also benefited from higher average FTE rates.    

      During the quarter, the Company increased its customer base to 316 customers, an increase from 237 customers as of December 31, 2010 and 282 as of March 31, 2011.

      Revenue from customers based in China rose by 202.7%.  The growth came from both local pharmaceutical companies and smaller domestic laboratories as well as major multinational biotech and pharmaceutical companies' Chinese R&D centers.  In light of the Chinese government's rising support of locally-developed drugs and more R&D investment into China by global pharmaceutical and biotech companies, the Company anticipates its China business will continue to grow and become a larger percentage of total revenues.

      Revenue from the Company's top-10 customers increased by 24.4% compared with the same period last year, and accounted for 61.8% of the total revenue compared with 62.6% in the same quarter last year.  The increase in top-10 customers' revenue has further demonstrated our continued efforts and commitments to become preferred business partners with global leading pharmaceutical and biotech companies.  In addition, percentage of revenue from top-10 customers as of total revenue has continued to decrease due to the very strong increase in revenue contribution from China-based clients and increased diversification of the customer base.

      Net revenues from full-time-equivalent ("FTE")-based services were $19.7 million, an increase of 26.5% from $15.6 million in the second quarter of 2010, primarily due to an increase in FTE numbers and higher FTE rates.

      Net revenues from fee-for-service-based services were $7.8 million, an increase of 24.9% from $6.2 million in the second quarter of 2010.  The rise was primarily driven by the Company's service offerings including discovery biology, preclinical development and newer biologics services. The growth in fee-for-service-based revenues reflects the Company's ability to cross-sell more services to existing customers as well as strong demand from new customers.  The Company also saw strong demand from customers that use multiple services.

      Gross profit was $9.1 million, an increase of 23.6% from $7.4 million in the second quarter of 2010, primarily due to the increase in revenues, operational efficiency improvements, and in particular, improvements in employee productivity.  The increase was partially offset by the continued appreciation of the Renminbi, higher material costs as a result of service mix and higher share-based compensation expenses.

      Non-GAAP gross profit was $9.5 million, an increase of 26.7% from $7.5 million in the second quarter of 2010, primarily due to the increase in revenues and operational efficiency improvements, and in particular, improvements in employee productivity. The increase was partially offset by the continued appreciation of the Renminbi and higher material costs as a result of service mix.

      Gross margin was 33.3%, compared with 33.9% in the second quarter of 2010, primarily due to continued Renminbi appreciation, higher share-based compensation expenses and higher material costs as a result of service mix, which was partially offset by operational efficiency improvements.  

      Non-GAAP gross margin was 34.7%, compared with 34.5% in the second quarter of 2010.  The improvement was primarily due to operational efficiency improvements, which was partially offset by continued Renminbi appreciation and higher material costs as a result of service mix.

      Operating expenses (selling and marketing, general and administrative) were $6.3 million, an increase of 51.8% from $4.2 million in the second quarter of 2010, primarily due to additional headcount resulting from a build-up of corporate managerial and supporting infrastructure during the second half of 2010, higher share-based compensation expenses and listed company related professional fees such as SOX404 consulting fees and others.

      Non-GAAP operating expenses were $5.4 million, an increase of 30.3% from $4.1 million in the second quarter of 2010, primarily due to additional headcount resulting from a build-up of corporate managerial and supporting infrastructure in the second half of 2010 and listed company related professional fees.

      The build-up of corporate managerial and supporting infrastructure was near completion at the end of 2010.  The management team believes that the current infrastructure will be sufficient to support the future growth of the Company in the coming years.

      Profit from operations was $2.8 million, a decrease of 12.7% from $3.2 million in the second quarter of 2010, primarily due to additional headcount resulting from a build-up of corporate managerial and supporting infrastructure in the second half of 2010, higher share-based compensation expenses and listed company related professional fees.  The decline was partially offset by the increase in gross profit.  

      Non-GAAP profit from operations was $4.2 million, an increase of 22.2% from $3.4 million in the second quarter of 2010.  The rise was primarily due to higher gross profit and was partially offset by additional headcount resulting from a build-up of corporate managerial and supporting infrastructure in the second half of 2010 and listed company related professional fees.

      Operating margin was 10.3%, compared with 14.8% in the second quarter of 2010.  The operational efficiency improvements were primarily offset by higher share-based compensation expenses and the continued appreciation of the Renminbi.

      Non-GAAP operating margin was 15.2%, compared with 15.7% in the second quarter of 2010.  The decline was primarily due to continued Renminbi appreciation and listed company related professional fees, which was partially offset by the operational efficiency improvements.

      Net income decreased 19.0% year-over-year to $3.4 million, primarily due to lower profit from operations and lower other income, including lower government subsidies and a smaller gain recognized on foreign exchange forward contracts.

      Non-GAAP net income was $4.7 million, an increase of 9.0% from $4.3 million in the second quarter of 2010, primarily due to higher non-GAAP profit from operations, which was partially offset by lower other income.  

      Diluted earnings per ADS were $0.18, which compares with $0.26 in the second quarter of 2010.  

      Non-GAAP diluted earnings per ADS were $0.25, which compares with $0.28 in the second quarter of 2010.

      Financial Position  

      As of June 30, 2011, the Company had cash and cash equivalents of $41.6 million and short term debt of $0.8 million. During the quarter, capital expenditures totaled $11.0 million, including $5.5 million related to the purchase of a 68,000 square foot new lab and office building which replaced the original 36,000 square foot facility in Chengdu. The purchased lab and office building allows us to reduce overall expenditures and improve our earnings over time.  With a strong balance sheet and sound financial position, the Company is well positioned to make targeted investments when opportunities arise.  

      Full Year 2011 Guidance

      The Company reconfirms its guidance for full year 2011.  The Company expects:

      • Net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010.  
      • Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010.
      • Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.

      This reflects the Company's current view and is subject to change.

      Conference Call

      ShangPharma will host a conference call and live webcast at 8am New York time on August 22, 2011 (8pm Beijing time on August 22, 2011).  A PowerPoint presentation accompanying the prepared remarks will be available on the Company's website shortly before the call.  

      The dial-in details for the live conference call are as follows:

      - U.S. Toll Free Number:  

      1.888.396.2369

      - International dial-in number:                                    

      +1.617.847.8710

      - China Toll Free Number:

      10 800 152 1490 (North)


      10 800 852 1490 (South)

      - Hong Kong Toll Free Number:

      800 96 3844

      Passcode:  SHP




      A live and archived webcast of the conference call will be available on the Investor Relations section of ShangPharma's website at www.shangpharma.com

      A telephone replay of the call will be available for seven days after the conclusion of the conference call from August 22, 2011 to August 29, 2011.

      The dial-in details for the replay are as follows:

      - U.S. Toll Free Number:

      1.888.286.8010

      - International Dial-in Number: :                                    

      +1.617.801.6888

       Conference ID:  

      64510327



      ABOUT SHANGPHARMA CORPORATION

      ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

      Safe Harbor: Forward-Looking Statements

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Among other things, the section titled "Full Year 2011 Guidance" and quotations from management in this press release, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

      About Non-GAAP Financial Measures

      To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earnings per ADS, each of which excludes expenses relating to or the effect of share-based compensation. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and non-GAAP Financial Data" set forth at the end of this press release.

      The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding expenses relating to or the effect of share-based compensation that may not be indicative of its operating performance. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its operating performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using non-GAAP financial measures excluding expenses relating to or the effect of share-based compensation is that these expenses and effects have been and will continue to be significant recurring expenses in the Company's business for the foreseeable future. Management compensates for these limitations by providing specific information regarding the GAAP amount excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliation between non-GAAP financial measures and their most comparable GAAP financial measures.

      For further information, please contact:


      ShangPharma Corporation

      In Shanghai, China
      Lan Xie
      VP of Finance and Operations
      E-mail: [email protected]


      Christensen

      In New York, US
      Kimberly Minarovich, +1 917-533-3268
      [email protected]

      In Hong Kong
      Tip Fleming, +852-9212-0684
      [email protected]



      SHANGPHARMA CORPORATION

      UNAUDITED CONSOLIDATED BALANCE SHEET

      (in thousands of U.S. dollars, except for ordinary share data)


       

       

      December 31,

      June 30,

       

       

      2010

      2011



       



      ASSETS




      Current assets:



       

       Cash and cash equivalents

      49,160

      41,550

       

       Restricted cash

      688

      840

       

       Accounts receivable, net

      16,908

      20,261

       

       Amounts due from related parties

      -

      99

       

       Inventories

      1,259

      2,065

       

       Prepayments and other current assets

      4,779

      4,567

       

       Deferred tax assets

      315

      -

       

      Total current assets

      73,109

      69,382


      Non-current assets:



       

       Derivative assets

      261

      -

       

       Property, plant, equipment and software, net

      60,147

      70,450

       

       Land use right, net

      4,221

      7,352

       

       Other long-term assets

      204

      791

       

      Total non-current assets

      64,833

      78,593

       

      Total assets

      137,942

      147,975






      LIABILITIES




      Current liabilities:



       

       Short-term bank borrowings

      755

      773

       

       Accounts payable

      10,549

      11,664

       

       Amounts due to related parties

      1,025

      1,502

       

       Salary and welfare payable

      4,040

      2,774

       

       Income tax payable

      1,910

      931

       

       Advance from customers

      1,650

      1,012

       

       Other payables and accruals

      4,477

      5,055

       

       Deferred tax liabilities

      -

      335

       

      Total current liabilities

      24,406

      24,046

       

      Total liabilities

      24,406

      24,046


      Commitments and contingencies








      EQUITY



       

      Ordinary shares (US$0.001 par value; 429,999,350 shares authorized;
      335,600,000 shares issued and outstanding as of December 31, 2010
      and June 30, 2011, respectively)

      336

      336

       

      Additional paid in capital

      78,989

      81,403

       

      Statutory reserves

      6,795

      6,795

       

      Retained earnings

      23,655

      30,019

       

      Accumulated other comprehensive income

      3,761

      5,376

       

      Total equity

      113,536

      123,929

       

      Total liabilities and equity

      137,942

      147,975



      SHANGPHARMA CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

      (in thousands of U.S. dollars, except for ADS(1) data and per ADS data)


       

       

      Three months ended

      Six months ended

       

       

      June 30,

      June 30,

       

       

      2010

      2011

      % Change

      2010

      2011

      % Change





       




       

      Net revenue

      21,826

      27,508

      26.0%

      41,554

      52,282

      25.8%

       

      Cost of revenue

      (14,421)

      (18,359)

      27.3%

      (27,209)

      (35,134)

      29.1%

       

      Gross profit

      7,405

      9,149

      23.6%

      14,345

      17,148

      19.5%





       





      Operating expenses



       




       

          Selling and marketing

      (558)

      (588)

      5.4%

      (1,074)

      (1,061)

      -1.2%

       

          General and administrative

      (3,606)

      (5,732)

      59.0%

      (6,904)

      (10,781)

      56.2%

       

      Total operating expenses

      (4,164)

      (6,320)

      51.8%

      (7,978)

      (11,842)

      48.4%

       

      Profit from operations

      3,241

      2,829

      -12.7%

      6,367

      5,306

      -16.7%





       




       

      Other income, net:

      1,417

      1,350

      -4.7%

      1,449

      2,403

      65.8%

       

      Income from operations before income taxes

      4,658

      4,179

      -10.3%

      7,816

      7,709

      -1.4%





       




       

      Income taxes

      (521)

      (827)

      58.7%

      (948)

      (1,347)

      42.1%

       

      Net income

      4,137

      3,352

      -19.0%

      6,868

      6,362

      -7.4%





       




       

      Allocation to preferred shareholders

      (1,042)

      -

      -100.0%

      (1,729)

      -

      -100.0%

       

      Net income attributable to ordinary shareholders

      3,095

      3,352

      8.3%

      5,139

      6,362

      23.8%





       





      Net income attributable to ordinary shareholders per ADS



       




       

          Basic

      0.27

      0.18

      -33.3%

      0.44

      0.34

      -22.7%

       

          Diluted

      0.26

      0.18

      -30.8%

      0.44

      0.34

      -22.7%





       





      Weighted average ADS outstanding



       




       

          Basic

      11,555,888

      18,653,713

       

      11,555,888

      18,649,105

       

       

          Diluted

      11,716,526

      18,820,194

       

      11,686,824

      18,883,968

       


      (1) Each ADS represents 18 ordinary shares.




      SHANGPHARMA CORPORATION

      RECONCILIATION OF UNAUDITED GAAP TO NON-GAAP FINANACIAL DATA

      (in thousands of U.S. dollars, except for ADS(2) data and per ADS data)


       

       

      Three months ended

      Six months ended

       

       

      June 30,

      June 30,

       

       

      2010

      2011

      %

      2010

      2011

      %

       

      GAAP gross profit

      7,405

      9,149

      23.6%

      14,345

      17,148

      19.5%

       

      GAAP gross margin

      33.9%

      33.3%

       

      34.5%

      32.8%

       


      Adjustments:



       




       

         Share-based compensation

      126

      390

      209.5%

      251

      988

      293.6%

       

      Non-GAAP gross profit

      7,531

      9,539

      26.7%

      14,596

      18,136

      24.3%

       

      Non-GAAP gross margin

      34.5%

      34.7%

       

      35.1%

      34.7%

       





       




       

      GAAP operating expenses

      (4,164)

      (6,320)

      51.8%

      (7,978)

      (11,842)

      48.4%


      Adjustments:



       




       

         Share-based compensation

      51

      959

      1780.4%

      102

      1,730

      1596.1%

       

      Non-GAAP operating expenses

      (4,113)

      (5,361)

      30.3%

      (7,876)

      (10,112)

      28.4%





       




       

      GAAP profit from operations

      3,241

      2,829

      -12.7%

      6,367

      5,306

      -16.7%

       

      GAAP operating margin

      14.8%

      10.3%

       

      15.3%

      10.1%

       


      Adjustments:



       




       

         Share-based compensation

      177

      1,349

      662.1%

      353

      2,718

      670.0%

       

      Non-GAAP profit from operations

      3,418

      4,178

      22.2%

      6,720

      8,024

      19.4%

       

      Non-GAAP operating margin

      15.7%

      15.2%

       

      16.2%

      15.3%

       





       




       

      GAAP net income

      4,137

      3,352

      -19.0%

      6,868

      6,362

      -7.4%

       

      GAAP net margin

      19.0%

      12.2%

       

      16.5%

      12.2%

       


      Adjustments:



       




       

         Share-based compensation

      177

      1,349

      662.1%

      353

      2,718

      670.0%

       

      Non-GAAP net income

      4,314

      4,701

      9.0%

      7,221

      9,080

      25.7%

       

      Non-GAAP net margin

      19.8%

      17.1%

       

      17.4%

      17.4%

       





       




       

      GAAP net income attributable to ShangPharma Corporation's ordinary shareholders per ADS, diluted :

      0.26

      0.18

      -30.8%

      0.44

      0.34

      -22.7%


      Adjustments:



       




       

         Share-based compensation

      0.02

      0.07

       

      0.02

      0.14

       

       

      Non-GAAP net income attributable to ShangPharma Corporation's ordinary shareholders per ADS, diluted:

      0.28

      0.25

      -10.7%

      0.46

      0.48

      4.3%





       




       

      Weighted average ADS outstanding - basic (Non-GAAP)

      11,555,888

      18,653,713

       

      11,555,888

      18,649,105

       

       

      Weighted average ADS outstanding - diluted (Non-GAAP)

      11,716,526

      18,820,194

       

      11,686,824

      18,883,968

       


      (2) Each ADS represents 18 ordinary shares.




      SOURCE ShangPharma Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.